Skip to main content

. 1991 Aug 3;303(6797):288. doi: 10.1136/bmj.303.6797.288

Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis.

L A Frenken ¹, H J van Lier ¹, P G Gerlag ¹, M den Hartog ¹, R A Koene ¹

PMCID: PMC1670465 PMID: 1888931

288

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Bommer J., Samtleben W., Koch K. M., Baldamus C. A., Grützmacher P., Scigalla P. Variations of recombinant human erythropoietin application in hemodialysis patients. Contrib Nephrol. 1989;76:149–158. doi: 10.1159/000417891. [DOI] [PubMed] [Google Scholar]
Eschbach J. W., Egrie J. C., Downing M. R., Browne J. K., Adamson J. W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987 Jan 8;316(2):73–78. doi: 10.1056/NEJM198701083160203. [DOI] [PubMed] [Google Scholar]
Eschbach J. W., Kelly M. R., Haley N. R., Abels R. I., Adamson J. W. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989 Jul 20;321(3):158–163. doi: 10.1056/NEJM198907203210305. [DOI] [PubMed] [Google Scholar]
Winearls C. G., Oliver D. O., Pippard M. J., Reid C., Downing M. R., Cotes P. M. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986 Nov 22;2(8517):1175–1178. doi: 10.1016/s0140-6736(86)92192-6. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES